Synapse - Works

Results (2146)

Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/ paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Meeting Abstract

Eskander, R. N.; Sill, M.; Miller, A.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M. S.; Canturia, G.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat sensitive ovarian cancer (OvCa)

Meeting Abstract

Liu, J. F.; Brady, M.; Matulonis, U. A.; Miller, A.; Kohn, E. C.; Swisher, E.; Tew, W.; Cloven, N.; Muller, C.; Bender, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

Meeting Abstract

Meric-Bernstam, F.; Makker, V.; Oaknin, A.; Oh, D. Y.; Banerjee, S.; Gonzalez Martin, A.; Jung, K. H.; Lugowska, I.; Manso, L. M.; Manzano, A.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)

Meeting Abstract

Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors

Meeting Abstract

McKean, M.; Dumbrava, E. E.; Hamid, O.; Merriam, P.; Call, J. A.; Feely, W.; Green, A.; Vaishampayan, U. N.; Moore, K. N.; Weroha, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)

Meeting Abstract

Shapiro, G. I.; Basu, B.; El-Khoueiry, A. B.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

Meeting Abstract

O'Cearbhaill, R. E.; Moore, K. N.; Yeku, O.; Liu, J. F.; Bouberhan, S.; Hamilton, E. P.; Hou, J. Y.; Van Nieuwenhuysen, E.; Papadimitriou, K.; Yoo, S. Y.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/ KEYNOTE-775

Meeting Abstract

Colomba, E.; Lorusso, D.; Mackay, H.; Moore, R.; Yonemori, K.; Kim, Y. M.; Sanli, U. A.; Xie, R.; Barresi, G.; McKenzie, J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Meeting Abstract

Dagogo-Jack, I.; Dowlati, A.; Guo, R.; Awad, M. M.; Swalduz, A.; Calvo, E.; Garcia, V. M.; Adjei, A. A.; Lorusso, P.; Punekar, S.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

Meeting Abstract

Patel, M. R.; Doi, T.; Koyama, T.; Falchook, G. S.; Friedman, C. F.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M. M.; Mattour, A. H.; Satoh, T.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save